Literature DB >> 7875199

Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance.

C H Ladel1, S Daugelat, S H Kaufmann.   

Abstract

Knock-out mice with defined major histocompatibility complex (MHC) deficiencies were infected intravenously with Mycobacterium bovis bacille Calmette Guérin (M. bovis BCG) to assess the relative impact of MHC class I- and II-dependent immune responses. Heterozygous control mice were capable of controlling growth of M. bovis BCG, although infection progressed chronically, as assessed by determination of colony-forming units. Furthermore, infected controls developed granulomatous lesions at the site of mycobacterial growth and delayed-type hypersensitivity (DTH) reactions after challenge with purified protein derivative of tuberculin. In vitro, spleen cells from heterozygous control mice produced high concentrations of interferon-gamma (IFN-gamma) after restimulation with mycobacterial antigens. In contrast, the MHC class II-deficient A beta-/- mice, which are virtually devoid of functional CD4 T cells, succumbed to M. bovis BCG infection. Furthermore, A beta-/- mice lacked DTH reactions to tuberculin and only few minute picnotic lesions were formed in livers of infected mice. Finally, spleen cells from infected A beta-/- mice failed to produce measurable IFN-gamma concentrations after restimulation in vitro with various mycobacterial antigen preparations. The capacity of beta 2-microglobulin (beta 2m)-deficient mice, which are devoid of CD8 alpha/beta T cells, to inhibit growth of M. bovis BCG was only slightly affected at low inocula, although significantly higher colony-forming units were detected in spleens. These knock-out mice developed strong DTH responses to tuberculin and their spleen cells produced high levels of IFN-gamma once reactivated by mycobacterial antigens. Furthermore, in livers of infected beta 2m-deficient mice, extravascular infiltrates developed which were more diffuse than those in infected control littermates. Remarkably, the beta 2m-deficient mice were substantially more susceptible to higher inocula of M. bovis BCG than their control littermates. Our data formally prove the essential role of MHC class II-dependent immune mechanisms in all relevant aspects of immunity to M. bovis BCG. In addition, our findings emphasize an important contribution of MHC class I-dependent immunity to effective anti-mycobacterial protection. We assume that CD4 T cells are highly effective in containing M. bovis BCG within distinct granulomatous lesions, but fail to eradicate their intracellular pathogens. It appears most likely that CD8 T cells are also required to achieve this goal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875199     DOI: 10.1002/eji.1830250211

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  77 in total

1.  Identification of distinct lymphocyte subsets responding to subcellular fractions of Mycobacterium bovis bacille calmette-Guérin (BCG).

Authors:  G Batoni; S Esin; M Pardini; D Bottai; S Senesi; H Wigzell; M Campa
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Mycobacterial infection of macrophages results in membrane-permeable phagosomes.

Authors:  R Teitelbaum; M Cammer; M L Maitland; N E Freitag; J Condeelis; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Granule-dependent cytolysis of Mycobacterium tuberculosis-infected macrophages by human gammadelta+ T cells has no effect on intracellular mycobacterial viability.

Authors:  J S Passmore; R H Glashoff; P T Lukey; S R Ress
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

4.  Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.

Authors:  C G Feng; U Palendira; C Demangel; J M Spratt; A S Malin; W J Britton
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Cellular interactions in bovine tuberculosis: release of active mycobacteria from infected macrophages by antigen-stimulated T cells.

Authors:  E Liebana; A Aranaz; F E Aldwell; J McNair; S D Neill; A J Smyth; J M Pollock
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

6.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Authors:  Daniel F Hoft; Azra Blazevic; Getahun Abate; Willem A Hanekom; Gilla Kaplan; Jorge H Soler; Frank Weichold; Larry Geiter; Jerald C Sadoff; Marcus A Horwitz
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

8.  Pathogen-related differences in the abundance of presented antigen are reflected in CD4+ T cell dynamic behavior and effector function in the lung.

Authors:  Parizad Torabi-Parizi; Nienke Vrisekoop; Wolfgang Kastenmuller; Michael Y Gerner; Jackson G Egen; Ronald N Germain
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

9.  Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice.

Authors:  A Geluk; V Taneja; K E van Meijgaarden; E Zanelli; C Abou-Zeid; J E Thole; R R de Vries; C S David; T H Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  Suboptimal Antigen Presentation Contributes to Virulence of Mycobacterium tuberculosis In Vivo.

Authors:  Patricia S Grace; Joel D Ernst
Journal:  J Immunol       Date:  2015-11-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.